Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04812106 · ClinicalTrials.gov registry record
Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 8
- Enrollment target
NCT04812106: Clinical Trial study, sponsored by Ultragenyx Pharmaceutical.
NCT04812106 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04812106 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or caregivers) to self-report information.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2022-10-27 |
Why NCT04812106 stopped before completion
NCT04812106 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04812106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04812106 about?
NCT04812106 is a clinical study titled "Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program". The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or caregivers) to self-report information.
What is the current status of trial NCT04812106?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2022-07-25. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT04812106?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04812106?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI